Cantor Fitzgerald Thinks This Pharma Stock Could Double

The analyst isn't concerned about UBX's trek to record lows

Deputy Editor
Mar 7, 2019 at 12:55 PM
facebook twitter linkedin


The shares of Unity Biotechnology, Inc. (NASDAQ:UBX) suffered an 11.2% drop yesterday -- and touched a record low of $9.05 -- after poorly received fourth-quarter earnings. Despite all this, Cantor Fitzgerald last night initiated coverage of UBX with an "overweight" rating and a price target of $21 -- more than double the stock's current perch. The analyst waxed optimistic on Unity's "portfolio with multiple blockbusters," citing an increasing market for the company's age-related disease treatments. 

Cantor Fitzgerald is in good company, with three "buy" or better ratings and not a single "sell" for UBX. Plus, the analyst's $21 price target is still lower than the consensus 12-month target of $25.40 -- a roughly 173% premium to current levels. 

The stock was trading around $17 -- its initial public offering (IPO) price -- to start the year, but is down more than 42% year-to-date, amid pressure from its 20-day moving average. However, UBX today is up 2.4% at $9.30. 

UBX Chart March 7

Should Unity Biotechnology extend its bounce from new-low territory, a short squeeze could propel the stock higher. Currently, the 5.16 million UBX shares sold short represent a whopping 20.3% of the stock's available float. It would take over a month to buy back all these pessimistic positions, at the equity's average daily trading volume.

JUST RELEASED: The Complete Guide to Earnings Season Profits

earn21cover"/>

  




 
Special Offers from Schaeffer's Trading Partners